TITAN

• Research type

  Research Study

• Full title

  Randomised controlled open-label trial of TPF induction chemotherapy in the surgical management of locally advanced head and neck cancer (T = taxane, P = cisplatin, F = 5-fluorouracil)

• IRAS ID

  66479

• Contact name

  Richard Shaw

• Eudract number

  2010-023195-22

• Research summary

  Although favourable outcomes are possible in earlier stages of Head and Neck Squamous Cell Carcinoma (HNSCC), the most disappointing survival and functional outcomes are concentrated amongst those with locally advanced disease.Attempts at intensification by the addition of chemotherapy to postoperative radiotherapy are often confounded by unacceptable toxicity. It has been suggested that in using induction chemotherapy, toxicity might be reduced but survival advantage maintained. A complete or good partial response might ameliorate the functional impact of the subsequent surgical ablation. An international consensus has recently formed around TPF as the optimum induction regimen for HNSCC in several positive phase III trialsTITAN evaluates the survival advantage, functional and economic outcomes of induction TPF prior to ablative surgery for locally advanced HNSCC. In the proposed feasibility study, we aim to assess acceptability of randomisation in this setting and the ability to complete scheduled treatment.

• REC name

  North West - Greater Manchester Central Research Ethics Committee

• REC reference

  11/NW/0149

• Date of REC Opinion

  16 Jun 2011

• REC opinion

  Further Information Favourable Opinion